- Title
-
CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
- Authors
- Zoni, E., Chen, L., Karkampouna, S., Granchi, Z., Verhoef, E.I., La Manna, F., Kelber, J., Pelger, R.C., Henry, M.D., Snaar-Jagalska, E., van Leenders, G.J., Beimers, L., Kloen, P., Gray, P.C., van der Pluijm, G., Kruithof-de Julio, M.
- Source
- Full text @ Oncogene
CRIPTO knockdown reduces invasion and tumor growth of human PCa cells in vivo. (a) PC-3M-Pro4Luc2_dTomato human PCa cells with scrambled shRNA control (NT) and shCRIPTO no. 2 shRNAs were injected into the duct of Cuvier to monitor extravasation and formation of distant growth in vivo (30 embryos injected per group). (b) CRIPTO knockdown reduces whole-body tumor burden at 4 dpi (days post injection). Error bars±s.e.m. (c) CRIPTO knockdown reduces the number of extravasated cells at 1 and 4 dpi at the caudal hematopoietic tissue. Error bars±s.e.m. **P<0.01 and ***P<0.001. EXPRESSION / LABELING:
|
GRP78 KD reduces invasion and tumor growth in vivo. A) PC-3MPro4Luc2_dTomato human prostate cancer cells with GRP78 knockdown were injected into the duct of Cuvier to monitor extravasation and formation of distant metastases in vivo with 30 embryos injected per group. B-C) GRP78 knockdown reduces extravasation and tumor growth significantly at 4dpi (days post injection) at the caudal hematopoietic tissue (CHT). No effect on tumor burden is observed. Error Bars ± SEM. (Blind observations). **, P<0,01. |